Clinical Research

NA-1: Clinical Trial Shows Neuroprotectant Drug Protects Brain Against Stroke Damage

A neuroprotectant drug has been shown to protect the human brain against the damaging effects of stroke. The clinical trial was a randomized, double blind, multi-center trial that was conducted in Canada and the USA. The study evaluated the effectiveness o ...

Article - News Staff - Oct 9 2012 - 9:28am

First Patient In Randomized Controlled Hypertension Trial Of AV-Coupler Enrolled

...

Article - News Staff - Oct 20 2012 - 1:30pm

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for its treatment and prevention of bacterial vaginosis (BV) with a proven cure rate of 80 percent already after one vaginal tablet.  Addressing the unmet needs o ...

Article - Anna Ohlden - Oct 28 2012 - 4:30am

Data On Mucosal Healing With HUMIRA In Patients With Active Ulcerative Colitis

...

Article - News Staff - Oct 24 2012 - 9:56am

Phase II All-oral Study Of Simeprevir And VX-135 For The Treatment Of Hepatitis C

Medivir AB has announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) p ...

Article - News Staff - Nov 3 2012 - 1:00pm

Phase 2 Study Of Zerenex For Treatment Of Non-Dialysis Dependent Chronic Kidney Disease Initiated

Keryx Biopharmaceuticals, Inc. has announced the initiation of a Phase 2 study of Zerenex (ferric citrate), an ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dia ...

Article - News Staff - Nov 3 2012 - 12:00pm

Glybera Is First Gene Therapy Approved By European Commission

Glybera is the first gene therapy approved by regulatory authorities in the Western world. niQure announced it has received approval from the European Commission for the gene therapy Glybera(R) (alipogene tiparvovec), a treatment for patients with lipopro ...

Article - News Staff - Nov 3 2012 - 10:38am

Stem Cell Therapy No Benefit In Heart Attack Recovery

Autologous stem cells from bone marrow 3 or 7 days following a heart attack did not improve heart function six months later, according to a new clinical trial.  The results of this TIME (Transplantation In Myocardial Infarction Evaluation) trial were prese ...

Article - News Staff - Nov 6 2012 - 10:25pm

Phase III Clinical Trial Of Regenerative Medicine For Heart Failure

Cardio3 BioSciences (C3BS) announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3 ...

Article - News Staff - Nov 22 2012 - 10:00am

Clinical Trial Of Intravenous Erwinaze For Acute Lymphoblastic Leukemia

...

Article - News Staff - Dec 4 2012 - 1:30pm